中文
FOR IMMEDIATE RELEASE
North Augusta, SC, July 15, 2025– AmbioPharm, a leading global peptide CDMO (Contract Development and Manufacturing Organization), is pleased to announce that Weiguo (Michael) Wang, Ph.D. has joined the company as Principal Researcher. With extensive experience in peptide manufacturing and technical operations, Dr. Wang plays a key role in advancing AmbioPharm’s Manufacturing Science & Technology (MS&T) function and supporting the company’s commitment to operational excellence.
In this role, Dr. Wang is responsible for ensuring smooth tech transfer from R&D and clients, translating processes into scalable manufacturing workflows, and supporting ongoing technical improvements across sites.
Dr. Wang earned his Ph.D. in Biochemistry from Nanjing University of Technology and has held roles at GL Biochemical Co., Nanjing GenScript Biotechnology Co., and Changzhou Hequan Pharmaceutical Co. His expertise includes developing complex peptide processes at scale, solving synthetic challenges, and guiding IND-enabling work for peptide-based drug candidates.
During his time at Nanjing GenScript Biotechnology Co, Dr. Wang focused on producing challenging peptides, achieving a delivery rate of 95% and a cancel rate below 1.6%. He has contributed to the process development of numerous clinical-stage peptides.
“With Dr. Wang’s deep knowledge of peptide manufacturing, we’re better equipped to support our client-partners with robust processes and faster, more reliable tech transfer. His role is central to helping us deliver on the promises we make to our client-partners.” said Brian Gregg, Chief Executive Officer of AmbioPharm.
About AmbioPharm
AmbioPharm is a global peptide CDMO founded in 2005 and headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at clinical and commercial stages. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA as well as other global regulatory bodies with excellent outcomes. Our mission is to accelerate your peptides to patients.